Compared with previously reported data, Chi-CHOEP did not reveal clear benefits from adding chidamide, a novel HDAC inhibitor, to the CHOEP regimen in patients with untreated PTCL, which needs to be validated in phase 3 randomized controlled trials. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.